PSGL1-deficient mice develop spontaneous pulmonary hypertension associated to systemic sclerosis.
Pulmonary arterial hypertension (PAH), one of the major complications of systemic sclerosis (SSc), is a rare disease with unknown etiopathogenesis and non curative treatments. As PSGL-1-/- mice develop a spontaneous SSc-like syndrome, the objective of this work was to analyze whether they develop PAH and molecular mechanisms involved. Doppler echocardiography was used to estimate pulmonary pressure; immunohistochemistry, to assess vascular remodeling; myography of dissected pulmonary artery rings, to analyze vascular reactivity. ELISA, to quantify the levels of AngII; Western blot, to measure AT1R, AT2R, eNOS and p-eNOS expression in lung lysates and Flow cytometry to determine cytokine production of immune cells and NO production by endothelial cells. In all cases, n = 4-8 mice per experimental group. PSGL-1-/- mice present lung vessel wall remodeling and reduced expression of pulmonary AT2R (>18-month-old female mice: WT 0.337±0.094 vs KO 0.189±0.072). With aging, PSGL-1-/- females have impaired up-regulation of ERα and develop lung vascular endothelial dysfunction coinciding with an increase in pulmonary AngII levels (WT 48.70±5.13 vs KO 78.02±28.09 pg/g lung tissue) and a decrease in eNOS phosphorylation, driving to reduced endothelial NO production. These events lead to reduction in PAAT/ET ratio in 33% of aged PSGL-1-/- females, indicating pulmonary hypertension. Importantly, we found expanded populations of IFN-γ-producing PSGL-1-/- T cells and B cells and reduced presence of regulatory T cells. PSGL-1 absence induces reduction of Treg, NO production and ERα expression and the increase of Angiotensin II in the lungs of female mice, favoring the development of PAH.